Research and Clinical Evidence

Research and clinical evidence show that ketamine can reduce depressive symptoms quickly for some adults, especially people with treatment-resistant depression. The strongest regulatory evidence is for esketamine nasal spray, while racemic ketamine is also studied and used in some clinical settings but is not FDA-approved for depression. Short-term results can be meaningful, yet the best dose, schedule, long-term maintenance approach, and fit for an individual still require clinical judgment.

Ketamine treatment is not a substitute for emergency care. If you are in immediate danger of harming yourself, call or text 988 in the United States or contact local emergency services.

What the evidence supports

The evidence is most developed for adults with major depressive disorder who have not responded adequately to prior antidepressant treatment. Researchers have studied intravenous racemic ketamine, an anesthetic medication, and intranasal esketamine, a related medicine. These are not interchangeable treatments. They differ in formulation, approved uses, delivery, monitoring, and the clinical studies behind them.

According to the U.S. Food and Drug Administration, it approved Spravato, an esketamine nasal spray, in 2019 for adults with treatment-resistant depression. FDA approval applies to the labeled use of esketamine, not to every form of ketamine used for depression.

Racemic ketamine has been evaluated in randomized controlled trials and is commonly discussed in the research literature as a rapid-acting option. A 2017 American Psychiatric Association consensus statement concluded that the available evidence supported short-term antidepressant effects while also calling for careful patient selection, monitoring, and more long-term data. That distinction remains useful: a rapid response after treatment does not by itself establish durable benefit or identify the right ongoing plan.

How strong is the evidence for depression?

Ketamine has stronger evidence for short-term symptom reduction than for a one-size-fits-all long-term treatment plan. In clinical trials, some participants improve within hours or days, which differs from the timeline often associated with conventional oral antidepressants. Individual response varies, and symptoms can return after an initial response.

For a reader considering treatment, the practical question is not simply whether ketamine can work. It is whether a clinician can explain the treatment goal, the formulation being considered, how response will be measured, what monitoring is planned, and what happens if benefits fade or side effects occur. Our guide to next steps for treatment-resistant depression can help frame that conversation.

FDA approval and off-label care

Spravato is the brand name for esketamine nasal spray. Its FDA-approved labeling includes use with an oral antidepressant for treatment-resistant depression and other specific labeled circumstances. The FDA requires administration under supervision in certified settings because sedation, dissociation, and other risks may require observation after dosing. See the current FDA prescribing information for Spravato for full indications, warnings, and monitoring requirements.

Racemic ketamine is FDA-approved as an anesthetic, not as a depression treatment. When a licensed clinician prescribes an approved medication for a use that is not in its FDA label, that is generally called off-label prescribing. Off-label use is not a statement about whether a treatment is appropriate for a particular person. It means the patient and clinician should discuss the evidence, uncertainties, alternative treatments, and safety plan with particular care.

What clinical trials can and cannot answer

Randomized controlled trials are designed to compare a treatment with a control condition while limiting bias. They can show whether a treatment produced different average outcomes in the people studied. They cannot guarantee the same result for a new patient, settle every question about repeated treatment over years, or replace a full medical and psychiatric assessment.

Ketamine research has several real limits. Studies may be small, use different doses or routes, and follow participants for limited periods. Ketamine can also produce noticeable subjective effects, which can make blinding difficult in a trial. Researchers continue to study durability, maintenance strategies, comparative effectiveness, and which patient factors may be associated with response.

These gaps are a reason to ask precise questions, not to dismiss all evidence or assume every claim is equally supported. A clinic should be able to distinguish established findings from its own treatment approach and should not present research on one formulation as proof of identical outcomes with another.

Safety and monitoring are part of the evidence

Research findings have to be considered alongside safety. Ketamine and esketamine can cause dissociation, sedation, increases in blood pressure, nausea, dizziness, or other effects. A person’s medications, health history, pregnancy status, substance-use history, and symptoms all matter. Read more about ketamine safety and side effects and review drug interactions and contraindications before making decisions with a clinician.

Do not adjust prescribed medications or combine ketamine with alcohol, cannabis, benzodiazepines, or other substances based on general online information. Interactions and risks depend on the substances involved and the person’s health. A prescribing clinician or pharmacist can review your full medication and supplement list.

How ketamine compares with other depression treatments

Ketamine is one option within depression care, not a replacement for every other treatment. Depending on the person and diagnosis, a care plan may include psychotherapy, medication changes, brain stimulation therapies, sleep and medical evaluation, or other evidence-based approaches. The comparison that matters is practical: expected benefit, timing, risks, treatment burden, prior response, access, and the quality of follow-up.

A faster possible onset does not remove the need for a broader plan. For some people, ketamine may be considered after multiple prior treatments have not helped enough. For others, untreated medical issues, medication interactions, active substance-use concerns, or a different diagnosis may change whether it is a suitable next step.

What ongoing research is trying to clarify

Current research continues to examine who is most likely to benefit, how long benefits last, how repeat treatment should be approached, and how ketamine-related care compares with other options. Studies also explore possible biological markers and mechanisms, including NMDA receptor activity and neuroplasticity. These ideas help explain why researchers are interested in ketamine, but they are not yet a reliable way to predict an individual outcome. See our overview of biomarkers and ketamine response for more context.

When reading new headlines, check whether the report concerns racemic ketamine or esketamine, the condition studied, the study design, the number of participants, the comparison group, and the length of follow-up. Those details often matter more than a broad claim that ketamine is either proven or unproven.